Sales of products including Vivitrol, Aristada, and Lybalvi increased due to strong market demand and new prescriptions.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sales of products including Vivitrol, Aristada, and Lybalvi increased due to strong market demand and new prescriptions.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Also in this story
- Skyclarys announced its international expansion into Brazil and the U.K. on July 22, 2025.
- Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.
- Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.
- Sooin was appointed Chief Business and Strategy Officer at Galapagos, which also announced a partnership with Gilead.
The entities involved
Coverage
Newest first; wire copies grouped- ZacksWhy Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report? A month has gone by since the last earnings report for Alkermes (ALKS). Shares have added about 4.7% in that time frame, outperforming the S